Compare BioNano Genomics Inc (BNGO) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs iShares MBS ETF — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while iShares MBS ETF trades at $93.69. The key difference: iShares MBS ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MBB | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | — |
52-Week High | $4.92 | $96.91 |
52-Week Low | $1.09 | $92.46 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
MBB, the iShares MBS ETF, trades at $93.26, down 0.49% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oversold oscillators suggest potential for a near-term bounce. Recent news highlights institutional activity, with some firms increasing stakes while others reduced positions. The ETF continues its dividend distributions, with the latest payment scheduled for July 2026.
The outlook for MBB is mixed, balancing a defensive income stream from mortgage-backed securities against interest rate sensitivity. The primary opportunity lies in its monthly dividend yield, appealing for income-focused investors. Key risks include Federal Reserve policy shifts impacting bond valuations and broader economic conditions affecting the housing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
